CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma.
about
P1343
Control of prostate cell growth: BMP antagonizes androgen mitogenic activity with incorporation of MAPK signals in Smad1Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signallingExpression of RAC 3, a steroid hormone receptor co-activator in prostate cancerThe RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7Diffusion-weighted MRI for monitoring tumor response to photodynamic therapy.Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell linesPrimitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cellsLongitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditionsVascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer.LL-37 as a therapeutic target for late stage prostate cancer.Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells.Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R.Identification of novel GRM1 mutations and single nucleotide polymorphisms in prostate cancer cell lines and tissues.Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cellsASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.Development of seven new human prostate tumor xenograft models and their histopathological characterization.Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograftCRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activitiesDietary n-3 polyunsaturated fatty acids enhance hormone ablation therapy in androgen-dependent prostate cancerThioredoxin Reductase 1 Expression and Castration-recurrent Growth of Prostate CancerAndrogen-regulated and highly tumorigenic human prostate cancer cell line established from a transplantable primary CWR22 tumor.TCTP is an androgen-regulated gene implicated in prostate cancer.The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer.Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP.NF-kappaB regulates androgen receptor expression and prostate cancer growth.Serially heterotransplanted human prostate tumours as an experimental modelSrc controls castration recurrence of CWR22 prostate cancer xenografts.Current mouse and cell models in prostate cancer research.On the origins of the androgen receptor low molecular weight species.Roles for the backdoor pathway of androgen metabolism in prostate cancer response to castration and drug treatment.Metastatic phenotype in CWR22 prostate cancer xenograft following castration.Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines.Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay.Divergent androgen regulation of unfolded protein response pathways drives prostate cancer.Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.Androgens induce oxidative stress and radiation resistance in prostate cancer cells though NADPH oxidase.14-3-3{eta} Amplifies Androgen Receptor Actions in Prostate Cancer.Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r.Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells
P2860
Q24337748-BD6E66BD-0C0C-4EF3-B227-A7123BB4E941Q24629299-D6DFB18E-741E-46C8-A926-E14976B4604CQ24648557-C721E786-0CA1-4B99-9B51-5F6D0C1A3DC7Q30370955-CF95DDBC-28B0-434C-9B3E-74DCDB57B584Q33647190-CEEDDBB7-A3FA-47C0-8FB2-DEC80818F021Q33766326-5A3A3669-92CC-47DC-9DD5-CD85DF3ACD37Q34126555-B1726918-D2ED-4618-8B84-0348A1B9E0D5Q34177229-98F83099-E218-4711-9A15-DF77FDA092E3Q34279214-38B9E133-9972-4D72-88F6-D7472049B7B1Q34344798-96A83525-EE6C-4251-97E8-ADA4B9802FF5Q34511108-43DA3D6E-97B3-436D-AE2F-DF439D9D71DDQ34982106-34DCA09F-9738-41CF-A455-C0EA9164917BQ35102980-0B083DFA-E856-4CFE-9478-FFFE7EE24A22Q35213199-132CE657-8A02-4030-8D73-68B291A7D183Q35221988-4C7BDF6D-6033-4355-8F1A-4D0D6205CD28Q35763908-A06F3CA1-8F67-45D4-B3AC-2BCED9A524EAQ35782119-BD818346-5EDE-4D5C-931A-F53FAA4E7E97Q35788627-4AADA547-ACFB-4F24-AA9E-12589BD59980Q35828490-41465ED8-60C2-4F1A-875B-7271187735D0Q36734925-A2CCC069-5B27-4120-BA50-61B014000B9FQ36869643-455BBCA1-C319-484B-A11E-888683C43D1DQ36944559-8124B2EE-753F-40A5-84DB-F1D6CDA72574Q37033465-8FE81EF7-1E1E-44CA-91DD-7B2833B12B63Q37074725-6F1D270D-5C61-4606-8817-4EA83DA30B79Q37161795-10FCC1F5-CAAF-48A7-B926-0147D3D51BE1Q37278416-25C5338C-2216-4373-8A22-8B4BF9B6A293Q37310963-2901215A-4DBA-4BB2-B7D3-6795FAA01C5BQ37481145-3BBB5A08-A60A-4716-A66D-4789FC099D7CQ38098499-63DFC14A-3895-4316-AC4A-A519B45A62AFQ38122085-B996E981-8127-40A5-BDD7-E64C839095EBQ38221851-FAB096B7-6F16-495B-9D9C-3A4FE2817040Q38280999-BEA8D739-F1B4-40EF-9107-C6DBBDEAE1C7Q38342443-14907D31-3FC8-4F27-BDFF-84E86B637B84Q38715405-D765FFF1-BA0E-47CC-8BF6-95DB0B1517E9Q38888506-FC0EDFE8-1B14-4B3C-AADC-D64045D8DF9AQ39384179-08F23939-5636-48B1-9132-8441F144D397Q39477655-EBC68733-D3A0-411C-9197-BA365165803BQ39765541-80AAECAE-5199-422F-8F29-EC692A491867Q39795389-20E0EBE3-3685-4B6A-B5C4-E1FA759B06EEQ39858784-32E8751C-B0DD-4C37-A554-A01410FF2223
P2860
CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
CWR22: androgen-dependent xeno ...... ary human prostatic carcinoma.
@en
CWR22: androgen-dependent xeno ...... ary human prostatic carcinoma.
@nl
type
label
CWR22: androgen-dependent xeno ...... ary human prostatic carcinoma.
@en
CWR22: androgen-dependent xeno ...... ary human prostatic carcinoma.
@nl
prefLabel
CWR22: androgen-dependent xeno ...... ary human prostatic carcinoma.
@en
CWR22: androgen-dependent xeno ...... ary human prostatic carcinoma.
@nl
P2093
P1433
P1476
CWR22: androgen-dependent xeno ...... ary human prostatic carcinoma.
@en
P2093
Edgehouse NL
Giaconia JM
Pretlow TP
Robinson D
Schwartz S
Wainstein MA
P304
P407
P4510
P577
1994-12-01T00:00:00Z